Fima E - Search Results

1

Involvement of immune responses in the eradication of IL-1 alpha gene-transduced tumour cells: mechanisms of tumour rejection and immunotherapeutical implications.

Apte RN, Douvdevani A, Zoller M, White RM, Dvorkin T, Shimoni N, Huleihel M, Fima E, Hacham M, Voronov E, et al. Apte RN, et al. Among authors: fima e. Folia Biol (Praha). 1994;40(1-2):1-18. Folia Biol (Praha). 1994. PMID: 7958060

2

IL-1 and pro-inflammatory cytokines produced by primary and transformed fibroblasts abrogate the tumorigenic potential of fibrosarcomas.

Apte RN, Douvdevani A, Huleihel M, Fima E, Hacham M, Shimoni N, Dvorkin T, Segal S. Apte RN, et al. Among authors: fima e. Folia Biol (Praha). 1992;38(3-4):240-57. Folia Biol (Praha). 1992. PMID: 1426419

3

Cytokine-induced tumor immunogenicity: endogenous interleukin-1 alpha expressed by fibrosarcoma cells confers reduced tumorigenicity.

Apte RN, Douvdevani A, Zoller M, White RM, Dvorkin T, Shimoni N, Fima E, Hacham M, Huleihel M, Benharroch D, et al. Apte RN, et al. Among authors: fima e. Immunol Lett. 1993 Dec;39(1):45-52. doi: 10.1016/0165-2478(93)90163-v. Immunol Lett. 1993. PMID: 8144190 Review.

4

Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness.

Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, Benharroch D, Shendler Y, Bjorkdahl O, Segal S, Dinarello CA, Apte RN. Song X, et al. Among authors: fima e. J Immunol. 2003 Dec 15;171(12):6448-56. doi: 10.4049/jimmunol.171.12.6448. J Immunol. 2003. PMID: 14662844

5

Expression of PKCeta in NIH-3T3 cells promotes production of the pro-inflammatory cytokine interleukin-6.

Fima E, Shahaf G, Hershko T, Apte RN, Livneh E. Fima E, et al. Eur Cytokine Netw. 1999 Dec;10(4):491-500. Eur Cytokine Netw. 1999. PMID: 10586115 Free article.

6

Opposing effects of IL-1 alpha and IL-1 beta on malignancy patterns. Tumor cell-associated IL-1 alpha potentiates anti-tumor immune responses and tumor regression, whereas IL-1 beta potentiates invasiveness.

Apte RN, Dvorkin T, Song X, Fima E, Krelin Y, Yulevitch A, Gurfinkel R, Werman A, White RM, Argov S, Shendler Y, Bjorkdahl O, Dohlsten M, Zoller M, Segal S, Voronov E. Apte RN, et al. Among authors: fima e. Adv Exp Med Biol. 2000;479:277-88. Adv Exp Med Biol. 2000. PMID: 10897428 Review. No abstract available.

7

PKCeta enhances cell cycle progression, the expression of G1 cyclins and p21 in MCF-7 cells.

Fima E, Shtutman M, Libros P, Missel A, Shahaf G, Kahana G, Livneh E. Fima E, et al. Oncogene. 2001 Oct 11;20(46):6794-804. doi: 10.1038/sj.onc.1204885. Oncogene. 2001. PMID: 11709714

8

Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46.

Bloushtain N, Qimron U, Bar-Ilan A, Hershkovitz O, Gazit R, Fima E, Korc M, Vlodavsky I, Bovin NV, Porgador A. Bloushtain N, et al. Among authors: fima e. J Immunol. 2004 Aug 15;173(4):2392-401. doi: 10.4049/jimmunol.173.4.2392. J Immunol. 2004. PMID: 15294952

9

PKCeta associates with cyclin E/Cdk2 complex in serum-starved MCF-7 and NIH-3T3 cells.

Shtutman M, Hershko T, Maissel A, Fima E, Livneh E. Shtutman M, et al. Among authors: fima e. Exp Cell Res. 2003 May 15;286(1):22-9. doi: 10.1016/s0014-4827(03)00087-9. Exp Cell Res. 2003. PMID: 12729791

10

Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy.

Arnon TI, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F, Galili R, Cerwenka A, Benharroch D, Sion-Vardy N, Porgador A, Mandelboim O. Arnon TI, et al. Among authors: fima e. PLoS One. 2008 May 14;3(5):e2150. doi: 10.1371/journal.pone.0002150. PLoS One. 2008. PMID: 18478075 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters